| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Richard A. Heyman is Director at ORIC and has filed Form 4s across 3 companies. From April 2020 to October 2026, the filings on record show 0 open-market purchases and 32 sales. Richard A. Heyman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.3M at current prices.
Historically, Richard A. Heyman's trades have earned a strong insider score of 73/100 across 42 rated trades. Over a 12-month horizon, 77.1% of those trades were profitable, with an average 12-month return of +35.1%.
The biggest single holding is ORIC (~$2.3M) as Director. The ORIC filings lean toward selling, a net 38,028 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 518 | $27.54 | $14,264.32 | -0.4% | -13.9% | -23.8% | |
| Sep 16, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,270 | $22.41 | $28,458.16 | -1.0% | +5.3% | -17.6% | |
| Aug 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,270 | $23.25 | $29,526.20 | -1.0% | +8.5% | -14.9% | |
| Jul 31, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 2,351 | $27.50 | $64,662.54 | -7.8% | +8.1% | -28.7% | |
| Jul 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,270 | $24.80 | $31,496.76 | -0.9% | +10.6% | -13.7% | |
| Jun 17, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,270 | $21.48 | $27,277.95 | -0.9% | +3.8% | +1.1% | |
| May 16, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,270 | $23.74 | $30,149.67 | -0.9% | -8.4% | -29.2% | |
| Apr 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 6,964 | $24.11 | $167,887.52 | -19.6% | +25.9% | -14.5% | |
| Mar 19, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,270 | $14.50 | $18,418.68 | -0.9% | +22.9% | +19.1% | |
| Feb 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,270 | $17.42 | $22,117.43 | -0.9% | +38.7% | +25.3% |